Company Profile
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest News
Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium
Edwards, The 'Cleanest Large-Cap Medtech Story,' Reverses After Quarterly Beat
SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls
Edwards lifts FY26 growth outlook following steady Q2 performance
| Sector | Healthcare |
| Industry | Medical Devices |
| Website | https://www.edwards.com |
| Audit Risk | 4 |
| Board Risk | 2 |
| Overall Risk | 2 |
| Market Cap | 47.58B |
| Trailing P/E | 49.18 |
| Forward P/E | 24.49 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | 1.68 |
| Forward EPS | 3.37 |
| Book Value | 17.9 |
| Price-to-Book | 4.62 |
| Short Ratio | 2.32 |
| Earnings Date | 07/23/2026 |
| Earnings Call Date | 07/23/2026 |
| Earnings Average | 0.74 |
| Earnings Low | 0.72 |
| Earnings High | 0.77 |
| Revenue Average | 1.68B |
| Revenue Low | 1.65B |
| Revenue High | 1.71B |